Nelson Moy
Gastroenterology · Angola, INNPI 1891951406
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 34.9% of the total.
Across 201 payments — averaging $25.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$752
- Madrigal Pharmaceuticals$453
- Regeneron Healthcare Solutions, Inc.$304
- Lilly USA, LLC$287
- Intercept Pharmaceuticals, Inc.$181
- plus $1K from 29 others
Across 2 payments — averaging $3616.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$7K
What the payments were for
- Food & beverage$5,03099%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $1,767 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $752 |
| Madrigal Pharmaceuticals | 21 | $453 |
| Regeneron Healthcare Solutions, Inc. | 10 | $304 |
| Lilly USA, LLC | 8 | $287 |
| Intercept Pharmaceuticals, Inc. | 6 | $181 |
| Sanofi | 4 | $164 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $133 |
| Eisai Inc. | 1 | $121 |
| Medical Device Business Services, Inc. | 1 | $111 |
| QOL Medical, LLC | 5 | $83 |
| Gilead | 3 | $69 |
| Urogen Pharma, Inc. | 2 | $68 |
| Pfizer | 3 | $54 |
| Shionogi Inc | 3 | $50 |
| Johnson & Johnson | 3 | $47 |
| Ardelyx, Inc. | 3 | $44 |
| AMAG Pharmaceuticals, Inc. | 2 | $40 |
| AstraZeneca | 2 | $32 |
| Exact Sciences | 2 | $30 |
| Echosens North America, Inc. | 2 | $27 |
| Tolmar, Inc. | 1 | $26 |
| Romark Laboratories, LC | 1 | $24 |
| Braintree Laboratories, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Organon | 1 | $20 |
| Bristol Myers Squibb | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Cook Medical LLC | 1 | $13 |
| Merck | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,071 in reported general payments places this provider in the 65th percentile of 323 gastroenterology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 21 | $49,262 |
| LinzessLinaclotide | 33 | $27,513 |
| Lansoprazole | 86 | $1,752 |
| Ursodiol | 15 | $1,679 |
| Omeprazole | 80 | $1,324 |
| Lactulose | 26 | $844 |
| Lubiprostone | 11 | $765 |
| Colestipol Hcl | 15 | $741 |
| Ondansetron OdtOndansetron | 38 | $467 |
| Pantoprazole Sodium | 44 | $419 |
| Famotidine | 23 | $291 |
| Dicyclomine Hcl | 15 | $187 |
| Sucralfate | 21 | $107 |
| Ondansetron Hcl | 20 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,767 | $76,77554 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 323 gastroenterology providers in Indiana.
Other gastroenterology in Angola
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Jonathan ObertNew Albany$302K
- Monika FischerIndianapolis$258K
- Naga ChalasaniIndianapolis$255K
- Matthew BohmWestfield$239K
- Thomas ImperialeIndianapolis$188K
- Mark GromskiIndianapolis$154K
- David PoundIndianapolis$137K
- Anoop AppannagariMunster$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.